✦ LIBER ✦

Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer

✍ Scribed by Tabchy, A.; Valero, V.; Vidaurre, T.; Lluch, A.; Gomez, H.; Martin, M.; Qi, Y.; Barajas-Figueroa, L. J.; Souchon, E.; Coutant, C.; Doimi, F. D.; Ibrahim, N. K.; Gong, Y.; Hortobagyi, G. N.; Hess, K. R.; Symmans, W. F.; Pusztai, L.

Book ID: 125535644
Publisher: American Association for Cancer Research
Year: 2010
Tongue: English
Weight: 343 KB
Volume: 16
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-10-1265

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacogenomic Predictor of Sensitivity

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

✍ Hess, K. R.; Anderson, K.; Symmans, W. F.; Valero, V.; Ibrahim, N.; Mejia, J. A. 📂 Article 📅 2006 🏛 American Society of Clinical Oncology 🌐 English ⚖ 362 KB

Pharmacogenomic Predictor of Sensitivity

Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

✍ Hayes, D.F. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

1–39 Gene Expression Profiles Predict Co

1–39 Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer

✍ Carey, L.A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 69 KB

A randomized multicenter trial of cyclop

A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer

✍ John M. Bennett; Patrick Byrne; Ajit Desai; Charles White; Ronald DeConti; Charl 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 388 KB

As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were post-

Docetaxel and Doxorubicin Compared With

Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial

✍ Nabholtz, J.-M. 📂 Article 📅 2003 🏛 American Society of Clinical Oncology 🌐 English ⚖ 150 KB

Is ERBB-2 A predictive marker for respon

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)

✍ P. De Crémoux; V. Diéras; V. Le Doussal; A. Vincent-Salomon; M. Tubiana-Hulin; J 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 120 KB